EPIENDO PHARMACEUTICALS (WWW.EPIENDO.COM)

EpiEndo Pharmaceuticals wins the Swedish American Life Sciences Summit (SALSS) Rising Star Award 2021

Retrieved on: 
Monday, October 25, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Death, Science, Lung, Wall Street, Inflammation, Industry, Patient, Epithelium, CEO, Richard Barker (life sciences and healthcare leader), Multimedia, Skin, List of life sciences, Female, Therapy, COVID, Pharmaceutical industry, EpiEndo Pharmaceuticals (www.epiendo.com), SALSS (www.salss.com), EPIENDO PHARMACEUTICALS (WWW.EPIENDO.COM), SALSS (WWW.SALSS.COM)

View the full release here: https://www.businesswire.com/news/home/20211025005415/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211025005415/en/
    Maria Bech, CEO and Dr Fridrik Gardarsson, Founder and Chief Innovation Officer of EpiEndo Pharmaceuticals, together with Gunnar Andersson, Honorary Consul of Austria, sponsor of the SALSS 2021 Rising Star Award sculpture.
  • SALSS is an exclusive, invitation-only conference that attracts some of the life science industrys most cutting-edge researchers, visionary entrepreneurs, prominent business leaders and investors.
  • SALSS 2021 is the 17th Annual Swedish American Life Sciences Summit, an exclusive, invitation-only annual conference that attracts some of the Life Science industrys most significant researchers, business leaders, entrepreneurs and investors.
  • The goal of SALSS is to generate collaboration and strategic relations between academia, industry and financiers, thus enhancing the global life science industry.

EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

Retrieved on: 
Wednesday, August 18, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Company, EIC, Reactive airway disease, Royal commission, Drug development, European Innovation Council, Therapy, Growth, Framework Programmes for Research and Technological Development, Prognosis, ABC, Inflammation, Skin, Macrolide, Infection, Research, Female, Disease, Health, COPD, Time, Fund, Forward-looking statement, Investment, Chronic obstructive pulmonary disease, Multimedia, CDMO, Azithromycin, Senior advisor, Patient, European Commission, CEO, Lung, Degenerative disease, Dermatology, Epithelium, Pharmaceutical industry, Bank, Creative industries, EpiEndo Pharmaceuticals (www.epiendo.com), ABC Ventures, the European Innovation Council Fund (eic.ec.europa.eu), Flerie Invest (www.flerie.com), Iðunn Venture Fund (www.kvikaeignastyring.is/en), EPIENDO PHARMACEUTICALS (WWW.EPIENDO.COM), ABC VENTURES, THE EUROPEAN INNOVATION COUNCIL FUND (EIC.EC.EUROPA.EU), FLERIE INVEST (WWW.FLERIE.COM), IðUNN VENTURE FUND (WWW.KVIKAEIGNASTYRING.IS/EN)

The financing secures funds to advance clinical development of EpiEndos lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.

Key Points: 
  • The financing secures funds to advance clinical development of EpiEndos lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
  • Using this Series A funding, EpiEndo aims to advance the clinical development of EP395 towards approval as the first disease modifying non-antibiotic macrolide that can be prescribed safely and effectively as a long-term treatment for patients with COPD.
  • We have followed EpiEndo for some time and have seen impressive progress towards clinical phase of their lead compound EP 395.
  • EpiEndos lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.